ADMA Biologics (NASDAQ:ADMA) Raised to Hold at Zacks Research

ADMA Biologics (NASDAQ:ADMA) was upgraded by research analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued on Monday,Zacks.com reports.

Other equities analysts also recently issued reports about the stock. Mizuho decreased their price target on shares of ADMA Biologics from $24.00 to $20.00 and set an “outperform” rating on the stock in a research note on Thursday, May 7th. Raymond James Financial assumed coverage on shares of ADMA Biologics in a research report on Wednesday, June 10th. They set an “outperform” rating and a $21.00 target price on the stock. Wall Street Zen downgraded shares of ADMA Biologics from a “buy” rating to a “hold” rating in a research report on Monday, May 4th. Cantor Fitzgerald reiterated a “neutral” rating on shares of ADMA Biologics in a research note on Thursday, March 26th. Finally, Canaccord Genuity Group reduced their price target on ADMA Biologics from $21.00 to $18.00 and set a “buy” rating on the stock in a research report on Thursday, May 7th. Three analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, ADMA Biologics currently has a consensus rating of “Moderate Buy” and an average target price of $19.67.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $9.21 on Monday. The stock has a market cap of $2.13 billion, a P/E ratio of 13.54 and a beta of 0.73. The stock has a 50 day simple moving average of $8.62 and a 200 day simple moving average of $12.82. The company has a current ratio of 6.95, a quick ratio of 3.93 and a debt-to-equity ratio of 0.51. ADMA Biologics has a 1-year low of $7.21 and a 1-year high of $20.46.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $0.19 EPS for the quarter, meeting analysts’ consensus estimates of $0.19. The firm had revenue of $114.49 million for the quarter, compared to analyst estimates of $139.98 million. ADMA Biologics had a return on equity of 39.98% and a net margin of 32.43%.The company’s revenue for the quarter was down .3% on a year-over-year basis. During the same period in the prior year, the firm posted $0.11 EPS. Research analysts anticipate that ADMA Biologics will post 0.82 earnings per share for the current year.

Insider Buying and Selling at ADMA Biologics

In other ADMA Biologics news, Director Jerrold B. Grossman bought 12,500 shares of ADMA Biologics stock in a transaction on Monday, May 11th. The shares were purchased at an average price of $8.01 per share, with a total value of $100,125.00. Following the acquisition, the director owned 513,884 shares in the company, valued at $4,116,210.84. This trade represents a 2.49% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 3.90% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Janus Henderson Group PLC grew its stake in shares of ADMA Biologics by 3,906.1% during the fourth quarter. Janus Henderson Group PLC now owns 3,936,419 shares of the biotechnology company’s stock worth $71,820,000 after buying an additional 3,838,158 shares during the last quarter. Capital Research Global Investors boosted its holdings in shares of ADMA Biologics by 104.0% during the 4th quarter. Capital Research Global Investors now owns 6,637,472 shares of the biotechnology company’s stock valued at $121,067,000 after acquiring an additional 3,383,559 shares in the last quarter. Caligan Partners LP bought a new stake in ADMA Biologics during the 3rd quarter worth $38,653,000. UBS Group AG grew its position in ADMA Biologics by 129.9% during the 4th quarter. UBS Group AG now owns 4,569,343 shares of the biotechnology company’s stock worth $83,345,000 after acquiring an additional 2,581,670 shares during the last quarter. Finally, Sachem Head Capital Management LP increased its holdings in ADMA Biologics by 27.0% in the 4th quarter. Sachem Head Capital Management LP now owns 11,375,000 shares of the biotechnology company’s stock worth $207,480,000 after purchasing an additional 2,415,000 shares in the last quarter. Institutional investors own 75.68% of the company’s stock.

Key ADMA Biologics News

Here are the key news stories impacting ADMA Biologics this week:

• Positive Sentiment: One market note from Zacks highlighted that ADMA Biologics had recently outperformed the broader market, reflecting some underlying trading resilience despite the legal headlines. Article Title
• Neutral Sentiment: Multiple law firms, including Rosen, Faruqi & Faruqi, Pomerantz, Robbins Geller, KSF, and others, issued reminders about the August 10, 2026 lead-plaintiff deadline in the already-filed securities class action. These notices do not change the case itself, but they keep the issue in the spotlight. Article Title
• Neutral Sentiment: The litigation centers on allegations that ADMA Biologics misled investors about revenue growth and internal controls during the August 9, 2024 to March 25, 2026 period. The claims are still allegations, but they add uncertainty around the company’s prior reporting. Article Title
• Negative Sentiment: The biggest headwind is the short-seller-related fraud narrative: several notices reference claims that ADMA’s reported ASCENIV revenue growth may have been overstated through channel stuffing, which reportedly helped trigger a sharp stock selloff. That allegation is the main reason shares are under pressure. Article Title

ADMA Biologics Company Profile

ADMA Biologics, Inc is a biopharmaceutical company headquartered in Ramsey, New Jersey, that focuses on the development, manufacturing and commercialization of specialty plasma-derived biologics for the treatment of primary immunodeficiency and infectious diseases. Leveraging an integrated model that spans plasma collection, fractionation, formulation and fill-finish operations, ADMA Biologics aims to address unmet needs in immune-compromised and high-risk patient populations.

The company’s marketed product portfolio includes BIVIGAM, a human immunoglobulin intravenous (IGIV) therapy approved by the U.S.